Market Overview:
The global malignant glioma drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of malignant gliomas, rising awareness about malignant gliomas and their treatment options, and the launch of novel therapies for the treatment of malignant gliomas. The global malignant glioma drugs market is segmented on the basis of type into alkylating agents, VEGF/VEGFR inhibitors, and anti-angiogenic drugs. The alkylating agents segment is expected to account for the largest share of the global market in 2018 owing to its large patient population and high adoption rate across regions. However, over time, this segment is projected to lose its share due to patent expirations and growing competition from newer therapies such as VEGF/VEGFR inhibitors and anti-angiogenic drugs.
Product Definition:
Malignant Glioma Drugs are used to treat cancerous tumors that form in the brain or spinal cord. They work by slowing or stopping the growth of the tumor cells.
Alkylating Agents:
Alkylating agents are a group of chemical substances that act as alkylating agents. Alkylation is the process in which an aliphatic compound is added to another molecule. The first step in this process involves the formation of an alkoxide (e.g., methoxide or ethoxide) and then addition of the desired compound, which results in a new molecule with two carbon chains and one oxygen atom (i.e., alkyl halide).
VEGF/VEGFR Inhibitors:
Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptor (VEGFR) are the two types of growth factors that control the abnormal growth of brain tumors. The drugs used for treating malignant gliomas inhibit both vascular endothelial growth factor and vascular endothelial growth factor receptor.
Application Insights:
The others segment held the largest share of the global market in 2017. This is due to an increase in research initiatives for other applications such as brain metastasis and spinal cord compression. For instance, a phase III clinical trial was conducted for evaluating VEGF inhibitor-based therapy for brain metastasis-associated glioma. The study was led by researchers from China and U.S., with collaboration from Germany, Japan, Korea and Australia among others (Neurology 2016). Such initiatives are expected to drive growth over the forecast period.
Hospitals were estimated as the largest application segment owing to increasing prevalence of cancer globally coupled with rising healthcare expenditure levels across various countries including India, China & Japan (OECD 2014).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, availability of newer generation drugs, high healthcare expenditure and awareness campaigns regarding malignant glioma diagnosis & treatment. Moreover, increasing R&D activities by major companies for development of novel molecules is also expected to drive growth during the forecast period. Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China & India. Furthermore, an increase in geriatric population base will further boost regional market expansion during the forecast period (2018-2030).
The emergence of new entities such as Sun Pharma’s Neotec AGS Medical Corporation along with other small scale manufacturers will fuel competition across Asia Pacific region thereby driving innovation.
Growth Factors:
- Increasing incidence of malignant glioma
- Rising demand for better treatment options for malignant glioma
- Growing awareness about malignant glioma and its treatment options
- Technological advancements in the field of malignant glioma drugs development
- Availability of government funding for research on malignant gliomas
Scope Of The Report
Report Attributes
Report Details
Report Title
Malignant Glioma Drugs Market Research Report
By Type
Alkylating Agents, VEGF/VEGFR Inhibitors, Anti Angiogenic Drugs
By Application
Hospitals, Cancer Research Organizations, Diagnostic Centers, Others
By Companies
Merck, Eli Lilly, AbbVie, Bristol-Myers Squibb, Genentech, Sun Pharmaceutical, BioMimetix, Cipla, Sigma-Aldrich, Panacea Biotec, Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
147
Number of Tables & Figures
103
Customization Available
Yes, the report can be customized as per your need.
Global Malignant Glioma Drugs Market Report Segments:
The global Malignant Glioma Drugs market is segmented on the basis of:
Types
Alkylating Agents, VEGF/VEGFR Inhibitors, Anti Angiogenic Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Cancer Research Organizations, Diagnostic Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Eli Lilly
- AbbVie
- Bristol-Myers Squibb
- Genentech
- Sun Pharmaceutical
- BioMimetix
- Cipla
- Sigma-Aldrich
- Panacea Biotec
- Merck
Highlights of The Malignant Glioma Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alkylating Agents
- VEGF/VEGFR Inhibitors
- Anti Angiogenic Drugs
- By Application:
- Hospitals
- Cancer Research Organizations
- Diagnostic Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Malignant Glioma Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Malignant glioma drugs are medications that are used to treat cancer. These drugs can help to shrink or stop the growth of tumors in the brain.
Some of the key players operating in the malignant glioma drugs market are Merck, Eli Lilly, AbbVie, Bristol-Myers Squibb, Genentech, Sun Pharmaceutical, BioMimetix, Cipla, Sigma-Aldrich, Panacea Biotec, Merck.
The malignant glioma drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Malignant Glioma Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Malignant Glioma Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Malignant Glioma Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Malignant Glioma Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Malignant Glioma Drugs Market Size & Forecast, 2020-2028
4.5.1 Malignant Glioma Drugs Market Size and Y-o-Y Growth
4.5.2 Malignant Glioma Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Alkylating Agents
5.2.2 VEGF/VEGFR Inhibitors
5.2.3 Anti Angiogenic Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Cancer Research Organizations
6.2.3 Diagnostic Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Malignant Glioma Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Malignant Glioma Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Alkylating Agents
9.6.2 VEGF/VEGFR Inhibitors
9.6.3 Anti Angiogenic Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Cancer Research Organizations
9.10.3 Diagnostic Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Alkylating Agents
10.6.2 VEGF/VEGFR Inhibitors
10.6.3 Anti Angiogenic Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Cancer Research Organizations
10.10.3 Diagnostic Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Alkylating Agents
11.6.2 VEGF/VEGFR Inhibitors
11.6.3 Anti Angiogenic Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Cancer Research Organizations
11.10.3 Diagnostic Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Alkylating Agents
12.6.2 VEGF/VEGFR Inhibitors
12.6.3 Anti Angiogenic Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Cancer Research Organizations
12.10.3 Diagnostic Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Alkylating Agents
13.6.2 VEGF/VEGFR Inhibitors
13.6.3 Anti Angiogenic Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Cancer Research Organizations
13.10.3 Diagnostic Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Malignant Glioma Drugs Market: Competitive Dashboard
14.2 Global Malignant Glioma Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Eli Lilly
14.3.3 AbbVie
14.3.4 Bristol-Myers Squibb
14.3.5 Genentech
14.3.6 Sun Pharmaceutical
14.3.7 BioMimetix
14.3.8 Cipla
14.3.9 Sigma-Aldrich
14.3.10 Panacea Biotec
14.3.11 Merck
